Disposition of [14C]-LY2835219 Following Oral Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2018
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary)
- Indications Brain cancer; Breast cancer; Cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 31 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.